1st National Spirometry Day 31st March 2004

Slides:

Advertisements

Similar presentations

New COPD GOLD Classification

Advertisements

BY DR.Khaled Helmy Chest Specialist Al Mahmora Chest Hospital Ministry of Health - Egypt COPD SCOPE ON.

or more simply.. -asthma is a condition of paroxysmal reversible airway obstruction which is characterised by : Airflow limitation ( reversible) Airway.

Academy Board Prep PCCM

AHM 2011 Alyn Morice University of Hull HYMS COPD Disease not Disorder?

Respiratory Function Tests RFTs

Physiology Lab Spirometry

2008 Guidelines 2.4 DIAGNOSIS IN ADULTS (1) -based on the recognition of a characteristic pattern of symptoms and signs and the absence of an alternative.

Clinical Characteristics of the Saguenay–Lac- St-Jean Familial Collection Subjects Families ProbandsAffected relativesUnaffected relatives n = 253n = 379n.

8 th ANNUAL CONGRESS OF TURKISH THORACIC SOCIETY April 27 – May 1, 2005 Antalya, TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN WORKERS OF FERROCHROME.

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

COPD MANAGEMENT FALLS SHORT AT RCRMC Jean Solomon, M.D.

Definition of COPD COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual.

Definition of COPD COPD is defined by GOLD (2014 update) as:*

Respiratory function tests

Interpretation Normal Spirometry Obstructive pattern Restrictive pattern Mixed pattern Small airway obstruction Non-specific ventilatory pattern Probably.

Respiratory COPD/Asthma.

Lung Volumes and Gas Distribution - Report Interpretation RET 2414L Pulmonary Function Testing Module 3.0.

Manila, Philippines. BOLD Manila, Philippines  COPD a growing cause of morbidity & mortality worldwide  5 th leading cause of death (2001)  3rd in.

Lung Function Tests Normal and abnormal Prof. J. Hanacek, MD, PhD.

Normal and abnormal Prof. J. Hanacek, MD, PhD

1 Pulmonary Function Tests J.B. Handler, M.D. Physician Assistant Program University of New England.

Respiratory Physiology Diagnostics North East Glasgow Roger Carter Consultant Clinical Scientist.

GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.

Real life COPD patients compared to large COPD study populations An UNLOCK external validity study A.L. Kruis, LUMC, Leiden, the Netherlands B. Stallberg,

Community based integrated intervention for prevention and management of Chronic Obstructive Pulmonary Disease in Guangdong, China: cluster randomised.

Andriy Lepyavko, MD, PhD Department of Internal Medicine № 2.

Spirometry A. H. Mehrparvar, MD Occupational Medicine department Yazd University of Medical Sciences.

Presenting Organization Event Name Event Date Presenter Name, Title COPD Essentials for Physicians

Aim To develop and to validate novel equations for ELA from varied anthropometric data and FEV 1. To develop and to validate novel equations for ELA from.

PULMONARY FUNCTION TESTING By: Gh. Pouryaghoub. MD Center for Research on Occupational Diseases (CROD) Tehran University of Medical Sciences (TUMS)

An Overview of Pulmonary Function Tests Norah Khathlan M.D. Consultant Pediatric Intensivist 10/2007.

Respiratory Function Tests RFTs. Review Of Anatomy & physiology Lungs comprised of  Airways  Alveoli.

COPD ) ) Chronic Obstructive Pulmonary Disease. Introduction n COPD is a preventable and treatable disease with some significant extrapulmonary effects.

DYNAMIC SPIROMETER By Dr. Maha al-Enazy. Objectives To understand the different measurements of lung volume To learn how spirometer works and the different.

Dr. Taj. What is Spirometry ? It is a measurement of the breathing capacity of the lungs. It is the most basic and frequently performed test of pulmonary.

Andriy Lepyavko, MD, PhD Department of Internal Medicine № 2.

Maggie Harris Independent Respiratory Nurse Specialist

Definition Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation and a range of pathological changes in the lung.

Pulmonary function tests & Lung volumes & capacities Prof. Omer Abdel Aziz.

Clinical Applications of Spirometry for Pediatric Asthma

Spirometry tests were carried out by a Respiratory Clinical Nurse Specialist (Respiratory CNS) Participants were referred to see their General Practitioner.

1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.

Roberto de Marco, Simone Accordini, Alessandro Marcon, Isa Cerveri Josep M. Anto, Thorarinn Gislason,Joachim Heinrich,Christer Janson, Deborah Jarvis,

 Dr. Jalal Mohsin Uddin  D.T.C.D,  F.C.P.S (Pulmonology)

By: James Simpson.  Why  What – now featuring definitions  When  Interpretation  CA$H MONEY.

External multicentric validation of a COPD detection questionnaire.

An effective COPD case finding strategy in Primary Care

Nigel Case study.

An Approach For Spirometry and DLCO Interpretation

PFT of the Day!.

Diagnosing Asthma in Symptomatic children using lung function: Evidence from a Birth Cohort Study Clare Murray1, Philip Foden1, Lesley Lowe1, Hannah Durrington1,

S Lungaro-Mifsud, S Montefort

Kjell Torén Section of Occupational and environmental medicine

2nd Eurasian Respiratory & Allergy Summit.

We have provided patients with diagnosis and

Kyrgyz State Medical Academy

Greater Glasgow Outreach Spirometry Service: A model for closer collaboration between primary and secondary care and its impact on chronic lung disease.

Lung volume and lung capacity By DR AGBARAOLORUNPO F

Nutritional status and COPD

Clinical application Dx exercise intolerance 1.1  VO2max   VO2 AT

Interpretation Normal Spirometry Obstructive pattern

یک عمر سلامت با خود مراقبتی

‘Moving in the right direction’

Predicted values for a, b) FEV1, c, d) FVC and e, f) FEV1/FVC by sex and ethnic group. a, c, e) Males and b, d, f) females. Predicted values for a, b)

20 minute update Asthma and COPD

Spirometry A. H. Mehrparvar, MD Occupational Medicine department

Lung function adjusted for body length and gestational age in male and female premature infants. Lung function adjusted for body length and gestational.

Presentation transcript:

1st National Spirometry Day 31st March 2004 Key figures Website visitors : 3,176 Calls to call centre : 8,483 Registrations for spirometry : >2,600 Participating centres : 79

1st National Spirometry Day 31st March 2004 Key problems Appointment system Last minute changes Patients who did not show up Patients who came without appointment Too few centres in major cities

1st National Spirometry Day 31st March 2004 Scientific Objectives : 1. Determine the prevalence of COPD and asthma in a selected group (possibly to be corrected by taking a random sample of the general population). 2. Examine whether PEFR is a valid method for the detection of COPD.

1st National Spirometry Day 31st March 2004 3. Examine to what extent MEFR and FEF75-25 are reduced in patients with COPD and linked to COPD more than to smoking.

Data analysis > 2,600 spirometries performed 1,901 spirometries collected 928 spirometries with flow-volume curve

Steering Commitee

Source of news (top 5) Newspaper 55% TV 27% Relative 5% Newspaper and TV 4% GP 3%

Gender Female 47% Male 53%

Region Brussels 20% Wallonia 32% Flanders 48%

History Family history asthma 24% Family history COPD 15% Personal history asthma 16% Personal history COPD 13% Occupational exposure 28%

Symptoms Cough 63% Expectoration 56% Dyspnoea 68% Wheezing 64% (Ex-) Smoking 71%

Symptoms 0 2% 1 7% 2 15% 3 22% 4 21% 5 21%

Smoking history <3 pack years 2% 4 pack years 1% 5 pack years 1%

Characteristics Age, yrs 55 ± 13 FVC, L 3.73 ± 1.00 FVC, % pred 102 ± 17 FEV1, L 2.81 ± 0.85 FEV1, % pred 94 ± 20 FEV1/VC 75 ± 10

Abnormal spirometry FEV1/FVC <70% 163 (24%) FVC <80% and 29 (4%)

Restrictive FVC < 80%pred FEV1/FVC ≥ 0.7

Asthma Age < 40 yrs History of asthma < 10 pack years

Abnormal spirometry COPD 11.8 % Restrictive 4.3 % Asthma 12.6 % Healthy 71.3 %

COPD (n=79) GOLD IV 1.3% GOLD III 10.1 % GOLD II 49.4% GOLD I 39.2%

150 130 110 90 PEFR (%) 70 50 30 30 50 70 90 FEV1/FVC

III II I GOLD FEV1/FVC FEV1 % 100 90 80 70 60 50 40 30 30 40 50 60 70 110 120 130 140 FEV1 %

FEF25-75 (%pred) FEV1/FVC (%)

Symptoms Control (n=92) Cough 2% Expectoration 3% Dyspnoea 1% Wheezing 2% (Ex-) Smoking 37%